ScholarIQanswers from OpenAlex

A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects

PaperCitations, authors & open-access status

A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects is a paper indexed in ScholarIQ from OpenAlex.

How many citations does A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects have?

ScholarIQcitation count

A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects has 25 citations in the OpenAlex counts ScholarIQ stores.

When was A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects published?

ScholarIQyear

A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects has 2020 year in the ScholarIQ index.

What is the open-access status of A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects?

ScholarIQoa status

A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects has closed oa status in the ScholarIQ index.

What is the DOI of A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects?

ScholarIQdoi

The DOI for A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects is on the source record.

What is the PMID of A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects?

ScholarIQpmid

The PMID for A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects is on the source record.

What is the OpenAlex record for A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects?

ScholarIQopenalex

The OpenAlex for A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial